Mark A Reynolds

USPTO Granted Patents = 29 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 2.7

ph-index = 14

Forward Citations = 950(Granted Patents)

Location History:

La Jolla, CA (US) (1997)
Lafayette, CO (US) (2000)
Pleasanton, CA (US) (2001)
San Diego, CA (US) (1996 - 2002)
Interlochen, MI (US) (2016)
Carlsbad, CA (US) (2013 - 2021)
Stamford, CT (US) (2018 - 2022)
Millbrae, CA (US) (2024)

Company Filing History:

Isis Pharmaceuticals, Inc.

patents

5. 1 out of 163

Incyte Genomics, Inc.

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2024

Loading Chart...

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12138250 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-11-12),

2. 12102621 - Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-10-01),

3. 11963950 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-04-23),

4. 11484535 - Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (2022-11-01),

5. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

6. 11035012 - Capture probes immobilizable via L-nucleotide tail (2021-06-15),

7. 10786489 - Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile (2020-09-29),

8. 10668072 - Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (2020-06-02),

9. 10137127 - Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (2018-11-27),

10. 9938590 - Capture probes immobilizable via L-nucleotide tail (2018-04-10),

11. 9267305 - Louvered snow plow (2016-02-23),

12. 8951730 - Compositions for detecting small RNAs (2015-02-10),

13. 8399222 - Compositions and methods for detecting small RNAs, and uses thereof (2013-03-19),

14. 6380169 - Metal complex containing oligonucleoside cleavage compounds and therapies (2002-04-30),

15. 6316608 - Combined polynucleotide sequence as discrete assay endpoints (2001-11-13),

Title: Innovations and Contributions of Mark A. Reynolds

Introduction

Mark A. Reynolds, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of biotechnology with a portfolio of 20 patents. His innovative work focuses on developing methods and tools for capturing target nucleic acids, showcasing his expertise in the domain of molecular biology.

Latest Patents

One of Reynolds' latest inventions is related to chimeric capture probes immobilizable via an L-nucleotide tail. This invention enhances the sensitivity and specificity of assays by utilizing L-nucleic acid tails that bind to corresponding L-nucleic acids in immobilized probes. The unique aspect of this technology is that the L-nucleic acid tails do not form stable duplexes with D-nucleic acids present in the sample, thereby reducing unwanted bindings and allowing for cleaner and more accurate results.

Career Highlights

Throughout his career, Mark A. Reynolds has held key positions in reputable biotechnology companies. Notably, he worked at Gen-Probe, Inc., which specializes in molecular diagnostics, and Genta Incorporated, focusing on cancer therapies and diagnostics. His experience in these organizations helped him refine his skills and contribute to critical advancements in genetic research.

Collaborations

In his journey as an inventor, Reynolds has collaborated with several professionals, including notable coworker Lyle J. Arnold Jr. These collaborations have enriched his perspective and fostered innovations that may not have been achievable in isolation.

Conclusion

Mark A. Reynolds continues to be a prominent figure in the life sciences field, driving forward innovative approaches to capture nucleic acids. His contributions not only enhance understanding in molecular biology but also pave the way for advancements in diagnostic and therapeutic technologies. His steadfast commitment to innovation exemplifies the impact that a dedicated inventor can have on both scientific research and real-world applications.

This text is generated by artificial intelligence and may not be accurate.